What Is a Post-Marketing Study and Why It Matters for COVID-19

Clinical Research Doesn’t End at FDA Approval

When a vaccine is authorized or approved by the FDA, it doesn’t mean the research stops there. In fact, that’s when another critical stage of medical research begins: the post-marketing study (sometimes called a post-approval trial). This type of study is designed to ensure that vaccines remain safe, effective, and relevant for everyone as time passes.

For COVID-19, this ongoing research is especially important as the virus continues to evolve, alongside our immune responses. For adults in their 50s and early 60s, post-marketing studies can be especially important, as this age demographic doesn’t always fit into “younger” or “older” data groups. In essence, post-marketing studies allow researchers to confirm that vaccines remain safe and effective across different ages and health backgrounds.

Here’s why post-marketing studies matter, and why studying this specific age group helps protect public health.

Why Focus on Adults Ages 50–64?

As people age, their immune systems change and gradually lose their ability to fight infections and disease—a natural process known as immunosenescence. Adults in their 50s and early 60s often respond differently to vaccines than younger adults, but they may not yet be fully represented in the “older adult” (65+) category that many studies prioritize. As a result, this age demographic typically receives less research during early-stage medical trials. A post-marketing study helps fine-tune vaccine schedules and recommendations for this in-between group, test efficacy and other key factors of the vaccine, and monitor any long-term effects.

Because the COVID-19 virus continues to mutate, it’s essential to also understand how vaccines perform over time. For adults 50–64, many of whom are active in the workforce and caring for both children and aging parents, staying protected has major public health and economic importance. Additionally, pre-approval studies don’t always capture the full range of health conditions common after age 50, such as diabetes, hypertension, or obesity. Post-marketing studies bridge this research gap, ensuring vaccine guidance reflects real-world outcomes rather than only controlled trial conditions.

Even after approval, regulators continue to monitor for rare side effects or long-term outcomes. A post-marketing study can identify safety signals early and confirm whether benefits continue to outweigh risks. It also informs any vaccine updates, such as booster intervals or new formulations.

Why Post-Marketing Studies Matter

The fight against COVID-19 doesn’t end with approval—it continues with every participant who volunteers for ongoing research. A post-marketing study makes sure vaccines remain safe, effective, and tailored to serve the people who need them most.

For adults in their 50s and early 60s, participation in this kind of research helps ensure their age group is fully represented in future vaccine recommendations. Because this demographic often falls between younger and older study groups, their involvement provides essential data that might otherwise be missed. For the broader community, participation also reinforces confidence that medical research is continuously working to protect us all through ongoing monitoring, updated guidance, and evidence-based decisions.

Get Involved in Health Research

At Health Research of Hampton Roads (HRHR), we believe clinical research is about more than just trials—it’s about building a safer, healthier future. By joining a study, you’re not only protecting yourself but also contributing to the health of your family, community, and beyond.

Explore our currently enrolling trials to learn more about how you can take part in ongoing COVID-19 vaccine research or play a direct role in shaping the future of public health through our other research opportunities.